Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.
Neetu SoniManish OraNamita MohindraY MendaGirish BathlaPublished in: AJNR. American journal of neuroradiology (2020)
Tumor resection followed by chemoradiation remains the current criterion standard treatment for high-grade gliomas. Regardless of aggressive treatment, tumor recurrence and radiation necrosis are 2 different outcomes. Differentiation of tumor recurrence from radiation necrosis remains a critical problem in these patients because of considerable overlap in clinical and imaging presentations. Contrast-enhanced MR imaging is the universal imaging technique for diagnosis, treatment evaluation, and detection of recurrence of high-grade gliomas. PWI and PET with novel radiotracers have an evolving role for monitoring treatment response in high-grade gliomas. In the literature, there is no clear consensus on the superiority of either technique or their complementary information. This review aims to elucidate the diagnostic performance of individual and combined use of functional (PWI) and metabolic (PET) imaging modalities to distinguish recurrence from posttreatment changes in gliomas.
Keyphrases
- high grade
- contrast enhanced
- low grade
- pet imaging
- computed tomography
- magnetic resonance imaging
- magnetic resonance
- high resolution
- diffusion weighted
- free survival
- end stage renal disease
- systematic review
- positron emission tomography
- type diabetes
- chronic kidney disease
- pet ct
- squamous cell carcinoma
- metabolic syndrome
- radiation therapy
- radiation induced
- adipose tissue
- newly diagnosed
- skeletal muscle
- diffusion weighted imaging
- weight loss
- photodynamic therapy
- rectal cancer
- fluorescence imaging
- patient reported outcomes
- social media